HARMON CYRUS (Chief Technology Officer) sold 3.4% of their position (25K shares) of OLEMA PHARMACEUTICALS, INC. on the open market
Open‑market sale worth $291.2K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 2 sales
Filed: 7/27/2026ACC: 0001831410-26-000008
DirectorOfficer· Chief Technology Officer
Since Nov 2020
-25K
Net shares
Net seller
$291.2K
Total sold
2
Open market trades
0B · 2S
2
Total transactions
25K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
−12.50K
Price / share
$11.58
Trade value
$144.74K
% of position
1.7%
7/23/2026
727.77K→715.27K
Common Stock
Direct
Shares
−12.50K
Price / share
$11.71
Trade value
$146.43K
% of position
1.7%
7/24/2026
715.27K→702.77K
Total
Net shares
−25K
Net value
-$291.16K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 7/23/2026 | S · Sale | −12.50K | $11.58 | $144.74K | 1.7% | 727.77K | 715.27K |
| Common Stock Direct | 7/24/2026 | S · Sale | −12.50K | $11.71 | $146.43K | 1.7% | 715.27K | 702.77K |
| Total | −25K | -$291.16K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)1
Common Stock
IndirectShares owned117.03K
Total
117.03K indirect117.03K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 117.03K | Indirect |
| Total | 117.03K | 117.03K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported